Global Liver Crisis: MASLD Affects 1.3 Billion, Projected to Rise to 1.8 Billion

A groundbreaking study published in *The Lancet Gastroenterology & Hepatology* journal has unveiled an alarming global health crisis: an estimated 1.3 billion people worldwide were living with Metabolic dysfunction-associated steatotic liver disease (MASLD) in 2023. This figure represents a staggering 143% increase in cases since 1990, underscoring the rapid and widespread progression of this condition. MASLD, previously known as non-alcoholic fatty liver disease (NAFLD), is a chronic liver condition characterized by excessive fat accumulation in the liver, not primarily caused by alcohol consumption. The renaming in 2023 reflects a broader understanding of the disease's metabolic origins and aims to reduce the stigma associated with the term 'fatty'. The study, based on comprehensive data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023, paints a stark picture of the increasing burden on public health systems worldwide. The researchers further project that if current trends continue, the global prevalence of MASLD could escalate to approximately 1.8 billion cases by the year 2050. This alarming projection is primarily attributed to sustained population growth coupled with significant shifts in global lifestyles. Key contributing factors include the soaring rates of obesity, elevated blood sugar levels (often indicative of type 2 diabetes), and other cardiometabolic risk factors. Geographical analysis within the study highlights pronounced disparities in MASLD prevalence. Regions such as North Africa and the Middle East reported disproportionately higher rates of the disease compared to other parts of the world. For instance, Kuwait recorded the highest national prevalence rate, while Finland reported the lowest, indicating that socioeconomic factors alone may not fully explain these differences. For an audience in India, these findings carry significant weight. Several reports indicate that India is grappling with a substantial and growing burden of liver disease. Times Now highlights that nearly 40% of the Indian population faces liver issues, often independent of alcohol consumption. Modern lifestyles, evolving dietary habits, and various environmental factors are silently contributing to liver damage across all age groups in the country. A separate analysis shows India experienced a sharp rise in MASLD prevalence, increasing by 23.19% between 1990 and 2023. The alarming statistic that liver failure accounts for around 250,000 deaths annually in India further underscores the urgency of addressing this public health crisis. MASLD represents a spectrum of liver conditions, ranging from simple steatosis (fatty liver) to more aggressive forms like metabolic dysfunction-associated steatohepatitis (MASH). MASH involves inflammation and liver cell damage, which can progress to fibrosis (scarring), cirrhosis (irreversible scarring that impairs liver function), and ultimately, hepatocellular carcinoma (liver cancer). A concerning aspect of MASLD and MASH is their often asymptomatic nature in early stages. Many individuals remain unaware of their condition until it has advanced to a severe stage, making early detection and intervention challenging. The study emphasizes the critical link between MASLD and other metabolic diseases. High blood sugar emerged as the primary global driver of MASLD-related health problems, followed by high body mass index (BMI) and smoking. This strong association with conditions like type 2 diabetes and obesity underscores the need for integrated public health strategies that address these interconnected metabolic disorders. The increasing prevalence of MASLD, particularly among younger adults in low- and middle-income countries, signifies a burgeoning challenge for healthcare systems that may not be adequately equipped to handle it. Despite the rising number of affected individuals, the overall impact on health, measured in years lost due to illness or death, has remained relatively stable, suggesting potential improvements in treatment and care in recent years. However, the sheer volume of new cases means that a larger population is now at risk of progressing to more severe outcomes such as liver cirrhosis or cancer in the future. Experts are calling for urgent action, including enhanced awareness campaigns, improved early detection mechanisms, and the prioritization of person-centered care for liver disease. The development of non-invasive tools and AI-based technologies for identifying at-risk patients in primary care settings is highlighted as a crucial step. For countries like India, where late detection is common and resources can be limited, low-cost diagnostic solutions using routine laboratory parameters like Neutrophil-Lymphocyte Ratio (NLR) and AST-to-Platelet Ratio Index (APRI) could be transformative in identifying high-risk patients and guiding faster clinical decisions. Effective treatments must go hand-in-hand with better diagnosis and comprehensive public health interventions aimed at promoting healthier lifestyles, balanced diets, and regular physical activity to curb the escalating global burden of MASLD.

Frequently Asked Questions

Read Full Story on Quick Digest